Geneva, July 7 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2041260070) titled 'Beeline: A Phase 1b/3 Study in GRIN-related Neurodevelopmental Disorder' on June 23.
Study Type: Interventional
Study Design:
randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose
Primary Sponsor: Chin Russell
Condition:
GRIN-Related Neurodevelopmental Disorder
Intervention:
PART A - PHASE 3 RANDOMIZED QUALIFYING SEIZURES COHORT: Based on a dose escalation regimen design, dosing will begin at 0.125 mg/kg of Radiprodil and will be sequentially increased to 0.25 mg/kg and 0.5 mg/kg, reaching the target dose of 0.75 mg/kg. Each dose level will be maintained for a...